Chronic kidney disease

National Kidney Foundation Recognizes March as National Kidney Month

Retrieved on: 
Thursday, February 29, 2024
African Americans, Chronic kidney disease, Hospital, National Kidney Foundation, ALL, Organ, MD, KDRI, NKF, Government, Risk, Federally Qualified Health Center, CKD, OPTN, Transplant, White, EGFR, Patient, Policy, Kidney disease, Priority, Kidney, Diagnosis, Mortality, Plague, FQHC, Kidney failure, Pharmaceutical industry

NEW YORK, Feb. 29, 2024 /PRNewswire/ -- As March approaches, the National Kidney Foundation (NKF) is gearing up to observe National Kidney Month, a crucial time dedicated to raising awareness about kidney health and chronic kidney disease (CKD). With World Kidney Day falling on Thursday, March 14th, this month holds particular significance in advocating for KIDNEY EQUITY FOR ALL™.

Key Points: 
  • NEW YORK, Feb. 29, 2024 /PRNewswire/ -- As March approaches, the National Kidney Foundation (NKF) is gearing up to observe National Kidney Month, a crucial time dedicated to raising awareness about kidney health and chronic kidney disease (CKD).
  • With World Kidney Day falling on Thursday, March 14th, this month holds particular significance in advocating for KIDNEY EQUITY FOR ALL™ .
  • "Despite this, they are exposed to inequities in kidney care including evaluation and obtaining a kidney transplant.
  • To mark National Kidney Month and World Kidney Day, NKF is highlighting several ways the organization is promoting kidney equity.

Evergreen Nephrology Names New Executive Leadership

Retrieved on: 
Thursday, February 29, 2024
CFO, Investment, Collection, Chronic kidney disease, CMO, MD, Quality of life, Associate, Growth, Evergreen, Transplant, Hope, Nephrology, CKD, Health, Humana, Organization, Patient, Kidney disease, Goldman Sachs, Insurance, Lazard, Partnership, Nursing

NASHVILLE, Tenn., Feb. 29, 2024 /PRNewswire/ -- Today, Evergreen Nephrology announced the appointment of two key executives to its leadership team, Chief Financial Officer (CFO) Philip Cooksey and Chief Medical Officer (CMO), Dr. Tim Pflederer.

Key Points: 
  • NASHVILLE, Tenn., Feb. 29, 2024 /PRNewswire/ -- Today, Evergreen Nephrology announced the appointment of two key executives to its leadership team, Chief Financial Officer (CFO) Philip Cooksey and Chief Medical Officer (CMO), Dr. Tim Pflederer.
  • Evergreen Nephrology announces appointment of executives, Philip Cooksey, CFO and Dr. Tim Pflederer, CMO.
  • Evergreen also welcomes Dr. Tim Pflederer, MD, who will begin his role as CMO on April 1.
  • These efforts can significantly improve the quality of life for patients living among the 37 million adults with kidney disease in the U.S.
    "In partnership with nephrology practices across the country, Evergreen works to delay disease progression, decrease unnecessary hospitalizations, shift care to the home, and increase transplants for CKD patients," says, Adam Boehler, Executive Chairman of Evergreen Nephrology.

Lupus Research Alliance Announces Recipients of the Lupus Mechanisms and Targets Award

Retrieved on: 
Wednesday, February 28, 2024
LRA, Engineering, Chronic kidney disease, LMTA, Immune system, Infection, Thrombus, Inflammation, Physician, Kidney disease, Quality of life, Lupus Research Alliance, Colchicine, Lupus, Nephritis, NETS, CD19, Skin, Cell, UV, Risk, Autoantibody, APS, Bacteria, Death, Agent handling, Mortal Kombat, Fibrosis, Clinical trial, Gene, Survival, Disease, Antiphospholipid syndrome, Kidney, SLE, S100A4, Research, DNA, Kidney failure, Vaccine

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).

Key Points: 
  • NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).
  • The development of targeted treatments is hindered by an incomplete understanding of lupus and its devastating complications.
  • These seven talented investigators will identify targets for new treatments and test novel therapeutic avenues to revolutionize the field and improve the lives of individuals with lupus.
  • Surgical biopsies of the kidneys are often needed to diagnose lupus nephritis (LN), kidney inflammation caused by lupus that can result in severe and sometimes life-threatening organ damage.

Avalon Saves Clients Millions, Sees Record Growth in 2023

Retrieved on: 
Tuesday, February 27, 2024
Chronic kidney disease, Insight, CKD, Organization, Patient, Policy, Genetic testing, Utilization management, Disease, Diagnosis, NCQA, Science, National Committee, HITRUST, Quality assurance, Medical device

TAMPA, Fla., Feb. 27, 2024 /PRNewswire/ -- Avalon Healthcare Solutions, the world's first Lab Insights company, enjoyed record-setting growth in 2023 while helping its health insurer clients save money, improve operations, and ensure the highest quality care for their members. That year, Avalon clients realized approximately 10% to 20% savings on their outpatient lab spending across lines of business. Approximately 25% of those savings benefit member spending and member out-of-pocket costs.

Key Points: 
  • TAMPA, Fla., Feb. 27, 2024 /PRNewswire/ -- Avalon Healthcare Solutions , the world's first Lab Insights company, enjoyed record-setting growth in 2023 while helping its health insurer clients save money, improve operations, and ensure the highest quality care for their members.
  • That year, Avalon clients realized approximately 10% to 20% savings on their outpatient lab spending across lines of business.
  • Due to this emphasis, Avalon experienced record growth in 2023.
  • Also, in 2023, Avalon launched Precision Genetic Testing Management (PGTM), the next evolution of its genetic test management solution.

Cure® Announces Five Winners of Cure Xchange Challenge: Health AI for Good

Retrieved on: 
Thursday, February 22, 2024
Xchange, DREAM, Cornell University, Doctor of Philosophy, Chronic kidney disease, X-Change, Amazon Web Services, Challenge, AI, Research, Education, MD, MIT, Social work, Mentorship, Weill Cornell Medicine, MBA, Food, MIT Solve, Federally Qualified Health Center, Economic development, Health, Therapy, JD, MIT Media Lab, Good, Health equity, Housing, NVIDIA, Medical device

NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Cure®, a healthcare innovation campus in New York City, today announced the five winning startup companies of its inaugural Cure Xchange Challenge: Health AI for Good. The winners will receive one-year residencies at Cure, unrestricted seed money, mentoring, in-kind resources and support services from Cure's partners, such as Amazon Web Services, ThermoFisher and NVIDIA.

Key Points: 
  • NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Cure® , a healthcare innovation campus in New York City, today announced the five winning startup companies of its inaugural Cure Xchange Challenge: Health AI for Good .
  • Oatmeal Health : AI-enabled cancer screening provider focused on delivering early-detection, health equity, and care coordination services for marginalized communities of Federally Qualified Health Centers (FQHCs) and Health Plans.
  • The event will include presentations from each winner and convene health, life science, and public sector leaders for discussions on AI in health.
  • The Cure Xchange Challenge: Health AI for Good is the inaugural challenge in a series that Cure is developing to foster and improve cross-disciplinary health innovation.

Novo Nordisk Foundation: Researchers aim to advance quantum sensing to transform disease diagnosis and prevention

Retrieved on: 
Thursday, February 22, 2024
Chronic kidney disease, Hospital, Senior, Novo Nordisk Foundation, Field line, Research, Moses Austin, Investment, Partnership, Quantum, Institute of technology, Niels Bohr Institute, Malnutrition, Nature, Myenteric plexus, University, Biomarker, Disease, Pediatrics, Diagnosis, Heart, Science, DSM-IV codes, Brain, Laboratory, Motion, Diamond, University of Copenhagen

The Copenhagen Center for Biomedical Quantum Sensing will be established with a grant of DKK 150 million from the Novo Nordisk Foundation.

Key Points: 
  • The Copenhagen Center for Biomedical Quantum Sensing will be established with a grant of DKK 150 million from the Novo Nordisk Foundation.
  • "Quantum sensing is among the most mature of the quantum technologies and holds the potential to greatly improve medical diagnostics.
  • The Novo Nordisk Foundation has recently made substantial investments in quantum technologies, including a grant to the Novo Nordisk Foundation Quantum Computing Programme and funding for Quantum Foundry Copenhagen P/S.
  • The international quantum sensing research collaboration will consolidate and significantly strengthen the quantum sensing activities in Denmark, fostering international synergy and promoting translation into clinical applications.

Novo Nordisk Foundation: Researchers aim to advance quantum sensing to transform disease diagnosis and prevention

Retrieved on: 
Thursday, February 22, 2024
Chronic kidney disease, Hospital, Senior, Novo Nordisk Foundation, Field line, Research, Moses Austin, Investment, Partnership, Quantum, Institute of technology, Niels Bohr Institute, Malnutrition, Nature, Myenteric plexus, University, Biomarker, Disease, Pediatrics, Diagnosis, Heart, Science, DSM-IV codes, Brain, Laboratory, Motion, Diamond, University of Copenhagen

The Copenhagen Center for Biomedical Quantum Sensing will be established with a grant of DKK 150 million from the Novo Nordisk Foundation.

Key Points: 
  • The Copenhagen Center for Biomedical Quantum Sensing will be established with a grant of DKK 150 million from the Novo Nordisk Foundation.
  • "Quantum sensing is among the most mature of the quantum technologies and holds the potential to greatly improve medical diagnostics.
  • The Novo Nordisk Foundation has recently made substantial investments in quantum technologies, including a grant to the Novo Nordisk Foundation Quantum Computing Programme and funding for Quantum Foundry Copenhagen P/S.
  • The international quantum sensing research collaboration will consolidate and significantly strengthen the quantum sensing activities in Denmark, fostering international synergy and promoting translation into clinical applications.

Black Health Matters Winter Health Summit and Expo Returns to Atlanta

Retrieved on: 
Wednesday, February 21, 2024
HCS, Blood pressure, Chronic kidney disease, Merck, Expo, Doctor of Philosophy, BHM, Anemia, Courage, Professor, Lunch, Conditional sentence, Amgen, Cholesterol, Blood, Obesity, DD, Conference, Health, Boehringer Ingelheim, STD, Maternal health, BMI, Lilly, JD, Radio, PSA, WAOK, Guru, Health equity, FREE, Interior design

NEW YORK, Feb. 21, 2024 /PRNewswire/ -- Following an incredibly successful inaugural event in 2023, Black Health Matters (BHM) is once more bringing its celebrated health summit series to Atlanta. On Saturday, March 2nd, 2024, the Black Health Matters Winter Health Summit & Expo will be held at the downtown Atlanta Loudermilk Conference Center, 40 Courtland St. N.E., from 8:30 AM to 4:00 PM EST. This FREE, hybrid (in-person and virtual) event will offer attendees a singular wellness experience, connecting dynamic experts on chronic illness and healthiness, patient advocates and celebrity guests with the public. Those who attend will benefit from free health screenings and immunizations, presentations on chronic disease management, invigorating fitness sessions, entertainment and more. Complimentary breakfast, lunch and parking will be offered, along with FREE giveaways and prizes. To register go to www.bhm2024wintersummit.com for in-person or virtual attendance.

Key Points: 
  • Theme is "Inspiration for Your Mind, Body and Soul"
    NEW YORK, Feb. 21, 2024 /PRNewswire/ -- Following an incredibly successful inaugural event in 2023, Black Health Matters (BHM) is once more bringing its celebrated health summit series to Atlanta.
  • On Saturday, March 2nd, 2024, the Black Health Matters Winter Health Summit & Expo will be held at the downtown Atlanta Loudermilk Conference Center, 40 Courtland St.
  • "The Winter Health Summit and Expo can be your ally on your path to better health and wellness," says Roslyn Young Daniels, founder, and president of Black Health Matters.
  • The Black Health Matters Winter Summit & Expo's impressive list of sponsors includes Amgen, Boehringer Ingelheim, Johnson & Johnson HCS Advocacy, Johnson & Johnson Innovative Medicine Clinical Trials, Lilly, Merck, Pfizer, and Vertex.

Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy

Retrieved on: 
Friday, February 16, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Chronic kidney disease, Commercialization, Caregiver, Multimedia, Food, BLA, Medication, IgA nephropathy, Risk, RAAS, OPDC, Life expectancy, Otsuka Pharmaceutical, Patient, Immunoglobulin A, Disease, Breakthrough therapy, Biology, Kidney failure, Pharmaceutical industry

Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease).

Key Points: 
  • Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease).
  • This press release features multimedia.
  • Breakthrough therapy designation allows the agency to prioritize and focus resources on the most promising products for which no satisfactory treatment option exists.
  • “We are encouraged by the FDA’s decision to grant breakthrough therapy status for the sibeprenlimab program,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer at Otsuka.

Pharmaceutical Patents Leader Duke Fitch Joins Troutman Pepper's National Health Sciences IP Team

Retrieved on: 
Wednesday, February 14, 2024
Private practice, Chronic kidney disease, University of Pennsylvania, Doctor of Philosophy, Anemia, GSK, Chemistry, FDA, Drug development, Temple University, Harvard University, Medication, CKD, University, JD, Patent, Daprodustat, Privacy, Pharmaceutical industry

BERWYN, Pa., Feb. 14, 2024 /PRNewswire/ -- Duke Fitch, a leading patent practitioner in the pharmaceutical and biotech industries, has joined Troutman Pepper's Health Sciences Intellectual Property Practice Group as a partner in its Berwyn, Pennsylvania office. Fitch joins the firm after spending more than two decades with the global pharmaceutical company GSK, including in his most recent position as vice president of Pharmaceutical Patents U.S.

Key Points: 
  • Fitch Boosts Firm's Patents Capabilities in Pharma, Biotech Sectors
    BERWYN, Pa., Feb. 14, 2024 /PRNewswire/ -- Duke Fitch , a leading patent practitioner in the pharmaceutical and biotech industries, has joined Troutman Pepper's Health Sciences Intellectual Property Practice Group as a partner in its Berwyn, Pennsylvania office.
  • Fitch joins the firm after spending more than two decades with the global pharmaceutical company GSK, including in his most recent position as vice president of Pharmaceutical Patents U.S.
    At Troutman Pepper, Fitch will assist clients in the life sciences and health care space with their intellectual property needs including patent portfolio development and management, licensing, and dispute matters.
  • "Duke is a known leader in the pharmaceutical and biotech sectors, and his expertise in patents will benefit our clients in these industries and beyond," said Sean Fahey, chair of Troutman Pepper's Health Sciences Department.
  • Troutman Pepper's leading life sciences and health care practice counsels clients at all stages of the health care continuum – from drug development to clinical care – from emerging biotech to global pharma.